Caption Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Caption Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40,000	Closed	-$164K	–	2002
2025 Q4	$164K	Sell	40,000 -30,000	-43%	-$149K	﹤0.01%	1407
2025 Q3	$342K	Buy	70,000 +30,000	+75%	+$158K	﹤0.01%	1384
2025 Q2	$202K	Hold	40,000	–	–	﹤0.01%	1257
2025 Q1	$212K	Sell	40,000 -217,200	-84%	-$1.58M	﹤0.01%	1265
2024 Q4	$1.74M	Buy	257,200 +52,500	+26%	+$353K	0.02%	739
2024 Q3	$1.35M	Buy	204,700 +30,000	+17%	+$215K	0.02%	691
2024 Q2	$1.31M	Buy	174,700 +64,700	+59%	+$564K	0.02%	589
2024 Q1	$1.1M	Buy	110,000 +85,000	+340%	+$947K	0.02%	706
2023 Q4	$247K	Buy	+25,000	New	+$178K	﹤0.01%	1088

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caption Management's RXRX Position: Q3 2025 in Review

Caption Management sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 420,801 shares — an estimated $2.21M sold.

Caption Management first reported a position in RXRX in Q4 2024 and held it in 2 quarters. The position peaked at $2.13M in Q2 2025. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

Caption Management reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Caption Management sold 420,801 Recursion Pharmaceuticals shares in Q3 2025, an estimated $2.21M.
Caption Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 2 quarters.
Caption Management's Recursion Pharmaceuticals position peaked at $2.13M in Q2 2025.
322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.